{"count": 4, "results": [{"_id": "35158983", "pmid": 35158983, "pmcid": "PMC8833738", "title": "Synthesis of Biotinylated PAMAM G3 Dendrimers Substituted with R-Glycidol and Celecoxib/Simvastatin as Repurposed Drugs and Evaluation of Their Increased Additive Cytotoxicity for Cancer Cell Lines", "journal": "Cancers (Basel)", "authors": ["Wróbel K", "Wołowiec S", "Markowicz J", "Wałajtys-Rode E", "Uram Ł"], "date": "2022-01-29T00:00:00Z", "doi": "10.3390/cancers14030714", "meta_date_publication": "2022 Jan 29", "meta_volume": "14", "meta_issue": "3", "meta_pages": "", "score": 50258.41, "text_hl": "In vitro studies performed with @SPECIES_9606 @@@human@@@ @DISEASE_Glioblastoma @DISEASE_MESH:D005909 @@@glioblastoma@@@ (@CELLLINE_CVCL:0633 @@@U-118 MG@@@) and @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@squamous cell carcinoma@@@ (@CELLLINE_CVCL:1681 @@@SCC-15@@@) cells revealed that dendrimer conjugate containing both @CHEMICAL_Celecoxib @CHEMICAL_MESH:D000068579 @@@celecoxib@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ was 20-50 times more potent than either drug administered alone or in combination. ", "citations": {"NLM": "Wróbel K, Wołowiec S, Markowicz J, Wałajtys-Rode E, Uram Ł. Synthesis of Biotinylated PAMAM G3 Dendrimers Substituted with R-Glycidol and Celecoxib/Simvastatin as Repurposed Drugs and Evaluation of Their Increased Additive Cytotoxicity for Cancer Cell Lines Cancers (Basel). 2022 Jan 29;14(3):. PMID: 35158983", "BibTeX": "@article{35158983, title={Synthesis of Biotinylated PAMAM G3 Dendrimers Substituted with R-Glycidol and Celecoxib/Simvastatin as Repurposed Drugs and Evaluation of Their Increased Additive Cytotoxicity for Cancer Cell Lines}, author={Wróbel K and Wołowiec S and Markowicz J and Wałajtys-Rode E and Uram Ł}, journal={Cancers (Basel)}, volume={14}, number={3}}"}}, {"_id": "30579354", "pmid": 30579354, "pmcid": "PMC6303879", "title": "Simvastatin, but not pravastatin, inhibits the proliferation of esophageal adenocarcinoma and squamous cell carcinoma cells: a cell-molecular study", "journal": "Lipids Health Dis", "authors": ["Chen Y", "Li LB", "Zhang J", "Tang DP", "Wei JJ", "Zhuang ZH"], "date": "2018-12-22T00:00:00Z", "doi": "10.1186/s12944-018-0946-7", "meta_date_publication": "2018 Dec 22", "meta_volume": "17", "meta_issue": "1", "meta_pages": "290", "score": 50076.098, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@, but not @CHEMICAL_Pravastatin @CHEMICAL_MESH:D017035 @@@pravastatin@@@, inhibits the proliferation of @DISEASE_Adenocarcinoma @DISEASE_MESH:D000230 @@@esophageal adenocarcinoma@@@ and @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@squamous cell carcinoma@@@ cells: a cell-molecular study", "citations": {"NLM": "Chen Y, Li LB, Zhang J, Tang DP, Wei JJ, Zhuang ZH. Simvastatin, but not pravastatin, inhibits the proliferation of esophageal adenocarcinoma and squamous cell carcinoma cells: a cell-molecular study Lipids Health Dis. 2018 Dec 22;17(1):290. PMID: 30579354", "BibTeX": "@article{30579354, title={Simvastatin, but not pravastatin, inhibits the proliferation of esophageal adenocarcinoma and squamous cell carcinoma cells: a cell-molecular study}, author={Chen Y and Li LB and Zhang J and Tang DP and Wei JJ and Zhuang ZH}, journal={Lipids Health Dis}, volume={17}, number={1}, pages={290}}"}}, {"_id": "24266317", "pmid": 24266317, "title": "Drug-related pityriasis rubra pilaris with acantholysis.", "journal": "Vojnosanit Pregl", "authors": ["Gajinov ZT", "Matić MB", "Duran VD", "Vucković N", "Prcić ST", "Vujanović LM"], "date": "2013-09-01T00:00:00Z", "doi": "10.2298/vsp1309871g", "meta_date_publication": "2013 Sep", "meta_volume": "70", "meta_issue": "9", "meta_pages": "871-3", "score": 50045.613, "text_hl": "CASE REPORT: Adult male @SPECIES_9606 @@@patient@@@ one week after the introduction of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ had experienced pruritic erythemo-@<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@squamous eruption@@@ on head and upper trunk that in a month progressed to erythrodermia, with islands of sparing. ", "citations": {"NLM": "Gajinov ZT, Matić MB, Duran VD, Vucković N, Prcić ST, Vujanović LM. Drug-related pityriasis rubra pilaris with acantholysis. Vojnosanit Pregl. 2013 Sep;70(9):871-3. PMID: 24266317", "BibTeX": "@article{24266317, title={Drug-related pityriasis rubra pilaris with acantholysis.}, author={Gajinov ZT and Matić MB and Duran VD and Vucković N and Prcić ST and Vujanović LM}, journal={Vojnosanit Pregl}, volume={70}, number={9}, pages={871-3}}"}}, {"_id": "19953096", "pmid": 19953096, "pmcid": "PMC2816649", "title": "A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion", "journal": "Br J Cancer", "authors": ["Hooper S", "Gaggioli C", "Sahai E"], "date": "2010-01-19T00:00:00Z", "doi": "10.1038/sj.bjc.6605469", "meta_date_publication": "2010 Jan 19", "meta_volume": "102", "meta_issue": "2", "meta_pages": "392-402", "score": 50031.84, "text_hl": "We find that @CHEMICAL_Lovastatin @CHEMICAL_MESH:D008148 @@@lovastatin@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ reduce matrix remodelling by fibroblasts and thereby reduce @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@SCC@@@ invasion. ", "citations": {"NLM": "Hooper S, Gaggioli C, Sahai E. A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion Br J Cancer. 2010 Jan 19;102(2):392-402. PMID: 19953096", "BibTeX": "@article{19953096, title={A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion}, author={Hooper S and Gaggioli C and Sahai E}, journal={Br J Cancer}, volume={102}, number={2}, pages={392-402}}"}}]}